This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AmerisourceBergen (ABC) Beats Q4 Earnings, Issues FY18 View
by Zacks Equity Research
Solid growth in the Pharmaceutical Distribution Services segment drove AmerisourceBergen's (ABC) top line in the fourth quarter.
STERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins Up
by Zacks Equity Research
STERIS (STE) witnessed year-over-year decline in Q2 revenues due to softness in Healthcare Products and the Healthcare Specialty Services segments.
Integra Gains on Global Growth, Hurricanes Hamper Business
by Zacks Equity Research
Integra (IART) launches new regenerative products within its Orthopedics and Tissue Technologies segment. However, hurricanes in Q3 grossly affect the wound care and orthopedic procedures in Florida.
Becton, Dickinson (BDX) Beats on Q4 Earnings, Guidance Solid
by Zacks Equity Research
Becton, Dickinson's (BDX) guidance for fiscal 2018 buoys optimism for investors. The company's Life Sciences business will be a key growth driver.
Zacks Market Edge Highlights: SPDR S&P 600 Small Cap, First Trust NASDAQ Community Bank, Ultra Clean, PetMed Express and MKS Instruments
by Zacks Equity Research
Zacks Market Edge Highlights: SPDR S&P 600 Small Cap, First Trust NASDAQ Community Bank, Ultra Clean, PetMed Express and MKS Instruments
Wright Medical Group (WMGI) Q3 Earnings In Line, Sales Miss
by Zacks Equity Research
Wright Medical (WMGI) posted loss as estimated in the third quarter on lower-than-expected sales.
Zimmer Biomet's (ZBH) Q3 Earnings Lag Estimates, View Down
by Zacks Equity Research
Zimmer Biomet's (ZBH) declining revenue performance within most of the core segments, along with a rise in cost of products sold resulted in bottom line pressure in the third quarter.
Masimo (MASI) Beats on Q3 Earnings and Revenues, Raises View
by Zacks Equity Research
Masimo (MASI) raises fiscal 2017 guidance. The year-over-year increase in both revenues and earnings encourages.
Is This a Buying Opportunity in Small Cap Stocks?
by Tracey Ryniec
The small caps have under performed this year but this earnings season is looking solid. Is the worst finally over?
IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.
Ecolab (ECL) Beats Earnings & Revenues in Q3, Cuts 2017 View
by Zacks Equity Research
Despite reporting solid third-quarter results, Ecolab (ECL) slashed its full-year earnings guidance, thanks to the hurricanes and the divestiture of the Equipment Care business segment.
Luminex (LMNX) Tops Q3 Earnings, Meets Revenue Estimates
by Zacks Equity Research
Luminex's (LMNX) third quarter saw a strong top line, solid cash flow as well as profits in Q3. The company's Assay business is likely to drive growth over the long term.
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q3
by Zacks Equity Research
Omnicell (OMCL) witnessed year-over-year growth in revenues on the back of its Medication Adherence segment in Q3.
Quality Systems (QSII) Beats on Earnings & Revenues in Q2
by Zacks Equity Research
Quality Systems' (QSII) solid total software, hardware revenues drove second-quarter earnings. A solid recurring revenue base is a key catalyst for the quarters to come.
Amazon.com (AMZN) Soars: Stock Adds 13.2% in Session
by Zacks Equity Research
Amazon.com (AMZN) saw a big move last session, as its shares jumped more than 13% on the day, amid huge volumes.
Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Abiomed's (ABMD) strong performance in Impella heart pump boosted the company's second-quarter 2018 results.
Top Ranked Momentum Stocks to Buy for October 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 30th:
Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues
by Zacks Equity Research
Integra LifeSciences' (IART) raised full-year 2017 revenue guidance buoys optimism.
Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales
by Zacks Equity Research
An extremely strong summer teen season drives Align Technology's (ALGN) Invisalign growth within the global teen market in the third quarter.
Chemed (CHE) Beats on Q3 Earnings & Revenues, View Revised
by Zacks Equity Research
Chemed (CHE) rides high on its Roto-Rooter business in Q3
ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines
by Zacks Equity Research
ResMed (RMD) delivers a promising Q1 on the back of solid contributions from domestic and international businesses.
Stryker (SYK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Stryker (SYK) posted strong numbers in the third quarter owing to higher revenues.
Cerner (CERN) Misses on Q3 Earnings, Bookings Decline Y/Y
by Zacks Equity Research
Despite a tepid third quarter, Cerner's (CERN) bookings guidance for the fourth quarter is encouraging.
Zacks.com featured highlights: Deckers Outdoor, PetMed Express, WABCO Holdings, United Rentals and CIT Group
by Zacks Equity Research
Zacks.com featured highlights: Deckers Outdoor, PetMed Express, WABCO Holdings, United Rentals and CIT Group
Varian Medical (VAR) Misses on Q4 Earnings, Issues FY18 View
by Zacks Equity Research
Year-over-year decline in Varian Medical's (VAR) proton therapy segment is the primary cause behind the company's lackluster fourth-quarter performance.